Advertisement

Clinical Rheumatology

, Volume 37, Issue 10, pp 2633–2641 | Cite as

Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study

  • Ali Ismail A. Al-GareebEmail author
  • Faiq Isho Gorial
  • Ahmed S. Mahmood
Original Article

Abstract

This study designed to identify the therapeutic efficacy of niclosamide (NCL) in Iraqi patients suffering from active rheumatoid arthritis (RA) who were using etanercept (ETN) for more than 3 months and still had high or moderate active RA. One hundred ten patients suffering from active rheumatoid arthritis (RA) who were using etanercept (ETN) for more than 3 months and still had high or moderate active RA were allocated randomly into two equal groups: one of them treated with 1000 mg/day NCL and the other treated with 1000 mg/day lactose in capsule dosage form. The study duration was 8 weeks. Clinical efficacy of the NCL was measured depending on scoring of the 28-joint Disease Activity Score (DAS28), simple disease activity index (SDAI), clinical disease activity index (CDAI), and Health Assessment Questionnaire Disability Index (HAQ-DI) at the baseline and at the end of the 8-week treatment period. Moreover, blood sample were taken from the patients at baseline and at after 8 weeks of treatment for measurement of the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), interleukin 1β (IL-1 β), interleukin-6, tumor necrosis factor (TNF-α), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin. At the end of the clinical study, patients had good response to NCL when added to the ETN with a high significant improvement in the SJC, TJC, DAS-28, CDAI, SDAI, and HAQ-DI compared to patients who were received placebo drug. In addition to that, 33% of patients achieved an ACR 20% response (ACR20) on NCL and ETN. Of these, 4% achieved ACR50 and another 4% achieved ACR70 response. While those group treated by placebo + ETN, 5% achieved ACR20 response and no one reached to ACR50 or ACR70 response. Twenty-seven percent of RA patients who have taken the NCL achieved moderate EULAR score while only 17% from the group that taken placebo with ETN achieved moderate response. On the other hand, no significant reduction was found in CRP, ESR, TNF-α, and IL-6, while IL-1 β reduced significantly after treatment with NCL. Treatment with NCL also exerts a significant lowering in the serum level of the E-selectin, ICAM1, and VCAM1 when compared to their value in baseline level. In RA disease, the use of NCL as adjuvant with ETN has resulted in a marked reduction in clinical assessment scoring indices and significantly decreased the E-selectin, ICAM-1, and VCAM-1 with marked improvement in the quality of life of patients.

Keywords

Etanercept Niclosamide Rheumatoid arthritis 

Notes

Acknowledgements

The authors would like to thank the medical staff of the Rheumatology Department, Baghdad Medical City, for their technical assistance. Also, sincere thanks to the laboratory staff in the Department of Outpatient Clinic, Baghdad Medical City, for their technical assistance.

Compliance with ethical standards

Disclosures

None.

References

  1. 1.
    Joshi VR (2012) Rheumatology, past present and future. J Assoc Physicians India 60:21–24PubMedGoogle Scholar
  2. 2.
    Salaffi F, Ciapetti A (2013) Clinical disease activity assessments in rheumatoid arthritis. Int J Clin Rheumatol 8(3):347–360CrossRefGoogle Scholar
  3. 3.
    Wasserman AM (2011) Diagnosis and Management of rheumatoid arthritis. Am Fam Physician 11:1245–1252Google Scholar
  4. 4.
    Papagoras C, Voulgari PV, Drosos AA (2010) Strategies after the failure of the first anti-tumor necrosis factor α agent in rheumatoid arthritis. Autoimmun Rev 9:574–582CrossRefPubMedGoogle Scholar
  5. 5.
    Detert J, Klaus P (2015) Biologic monotherapy in the treatment of rheumatoid arthritis. Biologics 9:35–43PubMedPubMedCentralGoogle Scholar
  6. 6.
    Bartok B, Firestein GS (2010) Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 233(1):233–255CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Bustamante Marta F, Garcia-Carbonell R, Whisenant Katrijn D, Guma M (2017) Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 19:110CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Cohen G, Gossec L, Dougados M, Cantagrel A, Goupille P, Daures JP, Rincheval N, Combe B (2007) Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis 66:358–363CrossRefPubMedGoogle Scholar
  9. 9.
    Wei C, Mook RA Jr, Premont RT, Wang J (2018) Niclosamide: beyond an antihelminthic drug. Cell Signal 41:89–96CrossRefGoogle Scholar
  10. 10.
    Huang M, Zeng S, Qiu Q, Xiao Y, Shi M, Zou Y, Yang X, Xu H, Liang L (2016) Niclosamide induces apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes. Int Immunopharmacol 31:45–49CrossRefPubMedGoogle Scholar
  11. 11.
    Elshabrawy HA, Chen Z, Volin MV, Ravella S, Virupannavar S, Shahrara S (2015) The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis 18:433–448CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Huang M, Qiu Q, Zeng S, Xiao Y, Shi M, Zou Y, Ye Y, Liang L, Yang X, Xu H (2015) Niclosamide inhibits the inflammatory and angiogenic activation of human umbilical vein endothelial cells. Inflamm Res 64:1023–1032CrossRefPubMedGoogle Scholar
  13. 13.
    Arnett FC , Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–24Google Scholar
  14. 14.
    Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K et al (2016) Clinical outcomes and biologic costs of switching between tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. Adv Ther 33:1347–1359CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Van Vollenhoven RF, Ernestam S, Harju A, Bratt J, Klareskog L (2002) Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. Arthritis Res Ther 5:R347–R351CrossRefGoogle Scholar
  16. 16.
    Bello AE, Perkins EL, Jay R, Efthimiou P (2017) Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatol 9:67–79CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Felson DT, LaValley MP (2014) The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing. Arthritis Res Ther 16:101CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, Weisman M, Wallace DJ, Crues J, Khanna D, Eckel G, Yeilding N, Callegari P, Visvanathan S, Rojas J, Hegedus R, George L, Mamun K, Gilmer K, Troum O (2007) Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 66:893–899CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Yongsong C, Oiling Y, Ke X, Jialin Z, Yuanbo L, Xiaoqing W et al (2016) Assessment of the therapeutic effect of total glucosides of peony for juvenile idiopathic arthritis: a systematic review and meta-analysis. Evid Based Complement Alternat Med 2016:1–13Google Scholar
  20. 20.
    Canhao H, Rodriguer AM, Gregorio MJ, Dias SS, Comes JA, Santos MJ et al (2018) Common evaluations of disease activity in rheumatoid arthritis reach discordant classifications across different populations. Frontiers in Medicine 5:1–8CrossRefGoogle Scholar
  21. 21.
    Feng J, Chen Q, Yu F, Wang Z, Chen S, Jin Z, Cai Q, Liu Y, He J (2016) Body mass index and risk of rheumatoid arthritis: a meta-analysis of observational studies. Medicine (Baltimore) 95(8):e2859CrossRefGoogle Scholar
  22. 22.
    Ai N, Wood RD, Yang E, Welsh WJ (2016) Niclosamide is a negative allosteric modulator of group I metabotropic glutamate receptors: implications for neuropathic pain. Pharm Res 33:3044–3056CrossRefPubMedGoogle Scholar
  23. 23.
    Liang L, Huang M, Xiao Y, Zen S, Lao M, Zou Y, Shi M, Yang X (2015) Xu H. Inhibitory effects of niclosamide on inflammation and migration of fibroblast-like synoviocytes from patients with rheumatoid arthritis. Inflamm Res 64:225–233CrossRefPubMedGoogle Scholar
  24. 24.
    Tokuhira M, Hosaka S, Volin MV, Haines GK 3rd, Katschke KJ Jr, Kim S et al (2000) Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis. Arthritis Rheum 43:1122–1133CrossRefPubMedGoogle Scholar
  25. 25.
    Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, Chwiecko J (2002) Soluble adhesion molecules (ICAM-1, VCAM-1 and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis 61:804–809CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ (1995) Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 376:517–519CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  1. 1.Department of Clinical Pharmacology College of Medicine, Mustansiriyah University BaghdadIraq
  2. 2.Department of MedicineCollege of Medicine, University of BaghdadBaghdadIraq
  3. 3.Department of PharmacyAl-Isra’a UniversityBaghdadIraq

Personalised recommendations